PMX 622

Drug Profile

PMX 622

Alternative Names: PMX-622; Polymixin B-dextran 70

Latest Information Update: 28 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antibacterials; Polymixins
  • Mechanism of Action Endotoxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Gram-negative infections; Sepsis

Most Recent Events

  • 31 Aug 2004 A preclinical study has been added to the pharmacokinetics and Bacterial Infections pharmacodynamics sections
  • 23 Feb 2000 Phase-II clinical trials for Sepsis in USA (IV)
  • 03 Dec 1998 Preclinical development for Sepsis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top